SCHEMBL20068820

SCHEMBL20068820

CN1CCC(C)(NC(=O)Cc2ccccc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ ALDH1A1 P00352 2/20 0.47
▸ SIGMAR1 Q99720 3/20 0.46
▸ DPP4 P27487 1/20 0.46
▸ HTT P42858 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ APAF1 O14727 1/20 0.46
▸ TDP2 O95551 1/20 0.46
▸ NSD2 O96028 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ KDM4C Q9H3R0 1/20 0.46
▸ ADRB2 P07550 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ HDAC8 Q9BY41 1/20 0.45
▸ HDAC6 Q9UBN7 1/20 0.45
▸ SCN1A P35498 1/20 0.44
▸ SCN2A Q99250 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20068818 0.92 NPC1 (0.46) NPC1RAB9AL3MBTL1ALDH1A1SIGMAR1
SCHEMBL17033023 0.88 MEN1 (0.53) ALDH1A1SIGMAR1HTTKDM4EAPAF1
SCHEMBL21465972 0.86 HSD11B1 (0.54) NPC1RAB9AALDH1A1SIGMAR1DPP4
SCHEMBL20147687 0.85 CNR2 (0.48) ALDH1A1SIGMAR1DPP4HTTKDM4E
SCHEMBL25504736 0.81 MEN1 (0.48) NPC1RAB9AALDH1A1SIGMAR1DPP4
SCHEMBL25225127 0.81 HTT (0.47) L3MBTL1ALDH1A1SIGMAR1HTTKDM4E
SCHEMBL20147684 0.80 CNR2 (0.46) ALDH1A1SIGMAR1DPP4HTTKDM4E
SCHEMBL25228282 0.79 GPR119 (0.56) KDM4EMEN1KMT2AHDAC8HDAC6
SCHEMBL10191097 0.79 CTSL (0.48) NPC1RAB9AALDH1A1SIGMAR1SCN1A
SCHEMBL5862098 0.79 SIGMAR1 (0.67) NPC1RAB9AALDH1A1SIGMAR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 — — US disclosed
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 — — US disclosed
WO-2018071454-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 NPC1 4145/4885RAB9A 632/4885L3MBTL1 2011/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 NPC1 4145/4885RAB9A 632/4885L3MBTL1 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback